ArriVent Biopharma, Inc.
ArriVent Biopharma, Inc. is listed today as ArriVent BioPharma, Inc.: market value, financials and filings are on its company page.
Funding rounds
2 counted as startup funding. Open the number of investors for the round's details.
| Month | Raised | Raise | Size | Investors | Sold | Filing |
|---|---|---|---|---|---|---|
| Dec 2022 | $110 M | No. 2 | $50 to $250 million | equity | SEC | |
| Jun 2021 | $150 M | No. 1 | $50 to $250 million | equity | SEC |
Source: SEC Form D. Each row is one private sale of securities with the running total of its newest notice. The form does not name the series or the investors; rounds are numbered in the order they were filed. A round's details show what its notice does say: accredited and other investors, the smallest investment taken, the exemption claimed, fees, the people named and the brokers paid to sell it.
How it makes money#
What its filings and its own website say, sentence by sentence, each with its source.
ArriVent Biopharma, Inc. chose not to state its revenue in its newest notice of a funding round (Dec 2022).
SEC Form D · Dec 2022
The industry group it chose in its notices: Biotechnology.
SEC Form D · Dec 2022
That is all the official record says: ArriVent Biopharma, Inc. has not published its revenue in a filing we can read, and no other official source covers it. Revenue figures come from crowdfunding filings (SEC Form C) and from annual reports once a company is listed.
Products and services#
No products or services of ArriVent Biopharma, Inc. are on record.
Investors#
5 named in official filings. Open an investor to see everything it has backed.
| Investor | Kind | Amount | Round | Role | Source |
|---|---|---|---|---|---|
| Hillhouse Capital Management, Ltd. | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner (Form 3, 2024) | SEC Form 3 |
| OrbiMed Advisors IV Ltd | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner, director (Form 3, 2024) | SEC Form 3 |
| Orbimed Advisors LLC | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner, director (Form 3, 2024) | SEC Form 3 |
| OrbiMed Asia GP IV, L.P. | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner, director (Form 3, 2024) | SEC Form 3 |
| OrbiMed Capital GP VIII LLC | Fund or asset manager | not stated | not stated | Held Series A and B preferred stock, 10% owner, director (Form 3, 2024) | SEC Form 3 |
Source: SEC Form 3 statements, SEC Form N-PORT fund reports, Wikidata, value.today research. Names come from filings that do name holders: the preferred stock each holder had when the company registered its shares (Form 3), private shares in US mutual funds' portfolio reports (N-PORT), and Wikidata. None ties a name to one funding round, so this list is per company, and it is not complete: the 2 rounds above had up to 17 investors.
Largest shareholders today
Institutions holding ArriVent BioPharma, Inc. shares, as of Sep 30, 2026.
- Montanova Capital, LLC$149 M9.52%
- Infinitum Asset Management, LLC$137 M8.75%
- Hhlr Advisors, LTD.$119 M7.60%
- BlackRock, Inc.$103 M6.59%
- Orbimed Advisors LLC$92 M5.85%
- FMR LLC$90 M5.74%
- Octagon Capital Advisors LP$65 M4.14%
- Vanguard Capital Management LLC$61 M3.89%
- Vivo Capital, LLC$54 M3.46%
- State Street Corp$53 M3.41%
- Sofinnova Investments, Inc.$51 M3.28%
- General Catalyst Group Management, LLC$45 M2.89%
- Logos Global Management LP$41 M2.61%
- Novo Holdings A/s$36 M2.27%
- Goldman Sachs Group Inc$34 M2.14%
Source: SEC Form 13F holdings reports · as of Sep 30, 2026. Value held and share of the company. All holders are on the company page.
Executives and directors
As the company named them in its notices. Directors of a funded startup are often partners of its investors.
| Name | Role | Named in |
|---|---|---|
| Zhengbin (Bing) Yao | Executive officer | Dec 2022 |
| Bahija Jallal | Director | Dec 2022 |
| Carl Gordon | Director | Dec 2022 |
| Cong Xu | Director | Dec 2022 |
| James Healy | Director | Dec 2022 |
| Jason Zhang | Director | Dec 2022 |
| Stuart Lutzker | Director | Dec 2022 |
| Zhengbin (Bing) Yao | Director | Dec 2022 |
Went public since 2024. Its SEC number is that of a company listed on a stock exchange.